Literature DB >> 23528564

Sclerosing cholangitis with autoimmune pancreatitis versus primary sclerosing cholangitis: comparison on endoscopic retrograde cholangiography, MR cholangiography, CT, and MRI.

Jin Hee Kim1, Jae Ho Byun, So Yeon Kim, Seung Soo Lee, Hyoung Jung Kim, Myung-Hwan Kim, Moon-Gyu Lee.   

Abstract

BACKGROUND: It is essential to differentiate sclerosing cholangitis with autoimmune pancreatitis (SC-AIP) from primary sclerosing cholangitis (PSC) as the treatment and prognosis of the two diseases are totally different.
PURPOSE: To compare image findings of SC-AIP and PSC on endoscopic retrograde cholangiography (ERC), magnetic resonance cholangiography (MRC), computed tomography (CT), and magnetic resonance imaging (MRI).
MATERIAL AND METHODS: Two radiologists retrospectively reviewed ERC, MRC, CT, and MRI in 28 SC-AIP and 23 PSC patients in consensus. Factors evaluated included the length, location, and multiplicity of bile duct stricture, the presence of characteristic cholangiographic features of PSC on ERC and MRC, and the presence, location, thickness, and pattern of bile duct wall thickening on CT and MRI.
RESULTS: On ERC, focal stricture, multifocal and intrahepatic bile duct stricture, and beaded, pruned-tree, and diverticulum-like appearance were more frequent in PSC than in SC-AIP patients (P ≤ 0.006). On MRC, multifocal and intrahepatic bile duct stricture and pruned-tree appearance were more frequent in PSC than in SC-AIP patients (P ≤ 0.044). On CT and MRI, the bile duct wall was thicker (5.1 mm vs. 3.1 mm; P = 0.033 and 4.3 mm vs. 3.0 mm; P = 0.01, respectively) in SC-AIP than in PSC patients. PSC was more frequently associated with intrahepatic bile duct wall thickening on both CT (93% vs. 50%; P = 0.024) and MRI (100% vs. 50%; P = 0.023) than SC-AIP.
CONCLUSION: The combination of ERC or MRC with cross-sectional images, including CT and MRI, may be helpful in differentiating between SC-AIP and PSC.

Entities:  

Keywords:  CT; MR; Sclerosing cholangitis with autoimmune pancreatitis; cholangiography; primary sclerosing cholangitis

Mesh:

Substances:

Year:  2013        PMID: 23528564     DOI: 10.1177/0284185113481018

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  8 in total

1.  Relapse of IgG4-related sclerosing cholangitis after steroid therapy: image findings and risk factors.

Authors:  Myung-Won You; Jin Hee Kim; Jae Ho Byun; Hyoung Jung Kim; Seung Soo Lee; Myung-Hwan Kim; Moon-Gyu Lee
Journal:  Eur Radiol       Date:  2014-02-28       Impact factor: 5.315

2.  Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.

Authors:  Sung-Hoon Moon; Myung-Hwan Kim; Jong Kyun Lee; Seunghee Baek; Young Sik Woo; Dong Hui Cho; Dongwook Oh; Tae Jun Song; Do Hyun Park; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  J Gastroenterol       Date:  2016-07-28       Impact factor: 7.527

3.  MR imaging and MR cholangiopancreatography of cholangiocarcinoma developing in printing company workers.

Authors:  Koichi Koyama; Shoji Kubo; Ai Ueki; Taro Shimono; Shigekazu Takemura; Shogo Tanaka; Masahiko Kinoshita; Genya Hamano; Yukio Miki
Journal:  Jpn J Radiol       Date:  2017-03-02       Impact factor: 2.374

4.  Differentiating IgG4-related sclerosing cholangiopathy from cholangiocarcinoma using CT and MRI: experience from a tertiary referring center.

Authors:  Jordan Swensson; Temel Tirkes; Mark Tann; Enming Cui; Kumaresan Sandrasegaran
Journal:  Abdom Radiol (NY)       Date:  2019-06

5.  Pancreatic duct abnormalities in focal autoimmune pancreatitis: MR/MRCP imaging findings.

Authors:  Riccardo Negrelli; Riccardo Manfredi; Beatrice Pedrinolla; Enrico Boninsegna; Anna Ventriglia; Sara Mehrabi; Luca Frulloni; Roberto Pozzi Mucelli
Journal:  Eur Radiol       Date:  2014-08-09       Impact factor: 5.315

Review 6.  Review of primary sclerosing cholangitis with increased IgG4 levels.

Authors:  Charis D Manganis; Roger W Chapman; Emma L Culver
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

7.  Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis.

Authors:  Miroslav Vujasinovic; Pia Maier; Hartwig Maetzel; Roberto Valente; Raffaella Pozzi-Mucelli; Carlos F Moro; Stephan L Haas; Karouk Said; Caroline S Verbeke; Patrick Maisonneuve; J-Matthias Löhr
Journal:  United European Gastroenterol J       Date:  2020-04-29       Impact factor: 4.623

8.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.